Edition:
United States

Jazz Pharmaceuticals PLC (JAZZ.OQ)

JAZZ.OQ on NASDAQ Stock Exchange Global Select Market

181.32USD
21 Jun 2018
Change (% chg)

$-1.86 (-1.02%)
Prev Close
$183.18
Open
$183.49
Day's High
$183.49
Day's Low
$180.80
Volume
16,592
Avg. Vol
142,014
52-wk High
$183.96
52-wk Low
$128.58

Chart for

About

Jazz Pharmaceuticals Public Limited Company is a biopharmaceutical company. The Company is focused on developing and commercializing products that address unmet medical needs. The Company has a diverse portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. The Company's lead... (more)

Overall

Beta: 0.99
Market Cap(Mil.): $10,872.71
Shares Outstanding(Mil.): 60.29
Dividend: --
Yield (%): --

Financials

  JAZZ.OQ Industry Sector
P/E (TTM): 38.45 29.56 34.04
EPS (TTM): 4.76 -- --
ROI: 6.26 13.58 13.11
ROE: 12.25 15.39 15.11

Jazz Pharmaceuticals to settle U.S. probe for $57 million

BOSTON Jazz Pharmaceuticals Plc said on Tuesday it had agreed to pay $57 million to resolve a U.S. probe into its financial support of charities that offer assistance to Medicare patients seeking help to cover out-of-pocket drug costs.

May 08 2018

UPDATE 2-Jazz Pharmaceuticals to settle U.S. probe for $57 million

BOSTON, May 8 Jazz Pharmaceuticals Plc said on Tuesday it had agreed to pay $57 million to resolve a U.S. probe into its financial support of charities that offer assistance to Medicare patients seeking help to cover out-of-pocket drug costs.

May 08 2018

Jazz Pharmaceuticals to settle U.S. probe for $57 million

BOSTON, May 8 Jazz Pharmaceuticals plc on Tuesday said that it had agreed to pay $57 million to resolve a U.S. probe into its financial support of charities that offer assistance to Medicare patients seeking help to cover out-of-pocket drug costs.

May 08 2018

BRIEF-Jazz Pharmaceuticals Reports Q1 Adjusted Earnings Per Share $2.98

* JAZZ PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS

May 08 2018

BRIEF-Jazz Pharma Submits Supplemental New Drug Application For Xyrem To Treat Cataplexy And Excessive Daytime Sleepiness In Pediatric Narcolepsy Patients

* JAZZ PHARMACEUTICALS SUBMITS SUPPLEMENTAL NEW DRUG APPLICATION FOR XYREM® (SODIUM OXYBATE) TO TREAT CATAPLEXY AND EXCESSIVE DAYTIME SLEEPINESS IN PEDIATRIC NARCOLEPSY PATIENTS Source text for Eikon: Further company coverage:

May 01 2018

BRIEF-Spark Therapeutics Says Entered Into Asset Purchase Agreement With Jazz Pharmaceuticals Ireland Ltd

* SPARK THERAPEUTICS SAYS ENTERED INTO ASSET PURCHASE AGREEMENT WITH JAZZ PHARMACEUTICALS IRELAND LIMITED - SEC FILING

Apr 30 2018

BRIEF-Jazz Announces FDA Acceptance Of NDA For Solriamfetol For Excessive Sleepiness Associated With Narcolepsy Or Obstructive Sleep Apnea

* JAZZ PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE OF NDA FOR SOLRIAMFETOL (JZP-110) FOR EXCESSIVE SLEEPINESS ASSOCIATED WITH NARCOLEPSY OR OBSTRUCTIVE SLEEP APNEA

Mar 02 2018

BRIEF-Jazz Pharmaceuticals Q4 GAAP Earnings Per Share $3.79

* JAZZ PHARMACEUTICALS ANNOUNCES FULL YEAR AND FOURTH QUARTER 2017 FINANCIAL RESULTS

Feb 27 2018

BRIEF-Jazz Pharmaceuticals Enrolls First Patient In Clinical Trial of Defibrotide

* JAZZ PHARMACEUTICALS ANNOUNCES FIRST PATIENT ENROLLED IN PHASE 2 CLINICAL TRIAL EVALUATING DEFIBROTIDE FOR THE PREVENTION OF ACUTE GRAFT-VERSUS-HOST DISEASE Source text for Eikon: Further company coverage:

Feb 23 2018

Earnings vs. Estimates